Respiratory drugs such as Cough Syrup and Synatrua Syrup were found to have been added as subjects for drug pricing negotiations under the Price-Volume Agreement (PVA) this year.

The use of the items had increased significantly last year due to the sharp increase in confirmed COVID-19 cases last year.

According to industry sources on the 7th, the National Health Insurance Service added 134 items and updated the list of drugs that completed drug pricing negotiations as ‘Type C PVA drugs’ recently.

Previously, the number of items subject to PVA Type C negotiations this time was known to be 138, and a similar number of items had been added to the list as those that